Paratek Still On Target

Paratek saw a major pullback since June, but the fundamentals are unchanged. The major breakout will come if it can get through the blue resistance line, which will happen in teh next year if it can exceed its 2021 high.

Earnings: Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

Prior posts on PRTK. I came across the stock while researching potential investments in case the U.S. onshores the manufacturing of precursor chemicals and basic medicines following shortages during the intial global lockdown. The company develops new antiobiotics to tackle new and existing diseases. My specualtive assumption is the company will benefit from an onshoring of supply chains because at minimum government grants will increase. The stock will benefit if this investment narrative draws in more investors. The company has deevloepd a new approved drug and aims to be cash flow positive by 2023. If that target holds, the stock-specific downside risk will be minimal from the current level.